EUCTR2010-019645-25-GB进行中（未招募）1 期
A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, with a 72 Week Dosing Extension. - SPD602-201
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Willing and able to sign the approved informed consent.
- •2.Age: 18-60 years old at Screening
- •3.Transfusional iron overload due to: hereditary anemias such as sickle cell disease, ß-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. Patients must also:
- •a.Be transfusion-dependent (8 or more transfusions annually) and
- •b.Require chronic treatment with deferoxamine, deferasirox, and/or deferiprone.
- •4.Willing to discontinue all existing iron chelation therapies for a minimum period of one to five days prior to first dose of SSP-004184, the 24 week duration of the study and 1 week after last dose for a total of approximately 26 weeks.
- •5.Serum ferritin > 500 ng/mL at Screening.
- •6.Baseline (Day -14 to Day -7) liver iron concentration (LIC) between =3.5 and <30 mg iron per g (equivalent, dry weight, liver) determined by FerriScan® MRI.
- •7.Baseline (Day -14 to Day -7) cardiac MRI T2* =10 milliseconds.
- •8.Mean of the previous three pre-transfusion hemoglobin concentrations = 7.5 g/dL.
- •9.Agrees to use an approved method of contraception from Screening and until 28 days after the last administration of the study drug. Agreed methods of contraception may include: condom; use of birth control pills, patches, implants or injections, diaphragm with vaginal spermicide, intrauterine device (IUD) and/or surgical sterilization (vasectomy or tubal ligation at least six months prior to dosing). Patients practicing abstinence must agree to use an approved method of contraception should they become sexually active during the study. A monthly pregnancy test will be performed on all female patients of child-bearing potential during the Screening and study period.
- •Requalification Inclusion Criteria (entry into 24 & 48 week extended dosing):
- •1.Willing to remain off all existing iron chelation therapies during FBS0701 dosing and 1 week after last dose for a total of approximately 50 - 98 weeks.
- •2.Have a serum ferritin above the upper limit of normal (>350 ng/mL) in the last assessment before Week 24/48.
- •3.Week 24/48 liver iron concentration (LIC) =2.0 mg iron per g (equivalent dry weight, liver) determined by FerriScan® MRI.
- •4.Week 24/48 cardiac MRI T2* =10 milliseconds.
- •5.Agree to continue to use an approved method of contraception until 28 days after the last administration of SSP-004184.
- •6.In the opinion of the Principal Investigator, sufficient compliance with study drug dosing to support continued use of SSP-004184.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.As a result of medical review, physical examination or Screening investigations, the Principal Investigator considers the patient unfit for the study.
- •2.Non-elective hospitalization within the 30 days prior to Baseline testing. (Patients with sickle cell anemia who are admitted to the hospital for management of sickle crisis pain whose uncomplicated hospital course was four days or less and who, 14 days prior to Baseline testing, have returned to their previous health status are acceptable.)
- •3.Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow or skin disorder as determined by the Investigator.
- •4.Evidence of significant renal insufficiency; e.g., serum creatinine above the upper limit of normal, proteinuria greater than 2 gm per day or calculated creatinine clearance of less than 60 mL/minute.
- •5.Cardiac left ventricular ejection fraction:
- •a.Outside the locally determined normal range in the 12 months prior to Screening by echocardiography or MRI or
- •b.<50% at Baseline testing by MRI
- •6.Known sensitivity to magnesium stearate, croscarmellose sodium or FBS0701.
- •7.Platelet count below 100,000/µL or absolute neutrophil count less than 1500/mm3 at Screening
- •8.Liver Function Tests
- •a.ALT >5 times the local upper limit of normal on two occasions in the previous 12 months or
- •b.ALT > 200 IU at Screening
- •9.Use of any investigational agent within the 30 days prior to the Baseline testing.
- •Requalification Exclusion Criteria (entry into 24 & 48 week extended dosing):
- •1.Has restarted prior chelation therapy. (NOTE: Ideally, patients will move directly from the initial dosing phase to the extended dosing phase with no pause in study drug dosing. Should there be an administrative need to interrupt study treatment, the patient may be allowed to remain off all chelator therapy for a maximum of 3 weeks prior to starting the extended phase of the study, should the Medical Monitor and the patient’s Principal Investigator deem it safe and clinically reasonable to do so.)
- •2.Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow or skin disorder as determined by the Investigator which in the view of the Investigator and the Medical Monitor represents an unacceptable risk to the patient.
- •3.Evidence of significant renal insufficiency; possible examples include: serum creatinine above the upper limit of normal, proteinuria greater than 2 gm per day or calculated creatinine clearance less than 60 mL/min in the last assessment prior to the Week 24/48 visit.
- •4.Platelet count below 100,000/µL or absolute neutrophil count less than 1500/mm3 in the last assessment prior to the Week 24/48 visit.
- •5.Serum ALT >200 IU/L in the last assessment prior to the Week 24/48 visit
- •6.At Week 48 only: Left Ventricular Ejection Fraction <55% by MRI
研究者
相似试验
进行中（未招募）
不适用
Treatment of chronic iron overload with a chelation therapy (FBS0701)Patients with transfusional iron overload, with the following primary diagnosis:hereditary anemia (such as sickle cell disease),ß-thalassemia and Diamond Blackfan anemiaEUCTR2011-005675-16-ITFERROKIN BIOSCIENCES INC.50
进行中（未招募）
不适用
A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. - NDPatients with transfusional iron overload due to hereditary anemias such as sickle cell disease, ß-thalassemia and Diamond-Blackfan anemiaacquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure.EUCTR2010-019645-25-ITFERROKIN BIOSCIENCES INC.40
已完成
2 期
Assessing the safety, tolerability, and pharmacodynamics of FBS0701 in the treatment of chronic iron overload requiring chelation therapyISRCTN17052121FerroKin BioSciences Inc. (USA)40
进行中（未招募）
1 期
Revaccination of healthy non-pregnantwomen with a second dose of a vaccine to asess its safety and the protection it gives from blood poisoning caused by a bacteriumHealthy person immune response to a second dose of Group B Streptococcuspolysaccharide capsule antigensMedDRA version: 18.1Level: PTClassification code 10053588Term: Group B streptococcus neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003094-15-BEGlaxoSmithKline Biologicals S.A.
进行中（未招募）
1 期
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 18.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-FRAstraZeneca AB240